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Urolithiasis is a worldwide disease which has affected humans from ancient eras to modern times.
Recently, societal changes have altered the epidemiology of urinary calculi. The incidence of urolithiasis
is higher in industrialized countries. Obese people are known to have a higher risk of stone formation.
Metabolic syndrome has resulted in an increasing rate of nephrolithiasis among women. There are many
useful tools for diagnosing urolithiasis, including conventional plain radiography, intravenous urography,
ultrasonography, computed tomography (CT), and nuclear medicine. Nonenhanced CT has high sensi-
tivities and speciﬁcities. It can be rapidly performed without intravenous administration of contrast
material and can therefore be used in patients with severely impaired renal function. Beyond that, it can
reveal extraurinary causes of ﬂank pain. However, concerns about radiation exposure and costs remain.
Since ancient times, hundreds of natural plant extracts and more recently, synthetic chemicals have been
proposed to eliminate urinary calculi. Clinical trials demonstrated that calcium channel blockers and
adrenergic antagonists are effective in enhancing stone passage. Shock wave lithotripsy (SWL) can
successfully treat renal calculi. A meta-analysis study revealed that SWL is more effective in treating
urinary calculi with a lower-frequency mode. Highly dense stones are more refractory to SWL. The stone
composition can be evaluated by preoperative CT attenuation values. Patients with preoperative
Houndsﬁeld units (HUs) of >750 have a 10.5-times greater chance of needing three or more sessions of
SWL treatment compared to patients whose HUs are <750. Ureteroscopy is a safe treatment for
managing ureter stones when performed by experienced hands and ureteroscopy is preferred over SWL
in patients with a larger upper-ureter stone, those who are pregnancy, and those with bleeding diathesis.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Humans have been affected by urinary stone diseases since at
least the ﬁrst identiﬁed case of Egyptian mummies dated to 4800
BCE. Urolithiasis still afﬂicts people to this day. With societal
changes, the incidence and epidemiology of urinary calculi have
changed. At present, urinary stones affect 10e12% of the population
in industrialized countries, and the peak incidence seems to be at
the ages of 20e40 years. Increasing rates of obesity, diabetes mel-
litus, andmetabolic syndrome have resulted in an increasing rate of
nephrolithiasis among women, decreasing the male-to-female
ratio from 1.7:1 to 1.3:1.1 This review summarizes recent data
regarding the inﬂuence of obesity on urinary calculi, imaging
modalities for detecting calculi, medical treatments, shock wave
lithotripsy (SWL), and ureteroscopy.th Road, Song Shan District,
ciation. Published by Elsevier Taiw2. Obesity and urolithiasis
Obesity is a manifestation of global societal changes. In 2005,
approximately, 400 million adults (aged over 15 years) were obese
[i.e., with a body-mass index (BMI) of >30 kg/m2], and 1.6 billion
adults were overweight (i.e., a BMI of >25).2 Relationships of
kidney stone disease with weight gain, BMI, and waist circumfer-
ence were well established by a recent large-scale prospective
study3 that reviewed three large cohorts: (1) the Health Profes-
sional Follow-up study that consisted of 51,529 male medical staff
aged 40e75 years; (2) the Nurses’ Health Study I that included
121,700 female registered nurses aged 30e55 years; and (3) the
Nurses’ Health study that included 116,671 female registered
nurses aged 25e42 years. In these studies, a greater weight was
associated with an increased risk of stone formation. The relative
risk (RR) for men weighing >100 kg compared to men weighing
<68.2 kg was 1.44. For older and younger women, the respective
RRs were 1.89 and 1.92. Weight gain that occurs in early adulthood
was also associated with increased risks of kidney stone formation
in both men and women. The RR for men who gained >15.9 kgan LLC. Open access under CC BY-NC-ND license.
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on stone risk factors and stone recurrence were investigated in 704
Korean stone formers, including 467 ﬁrst-time formers (FSFs) and
247 recurrent stone formers (RSFs).4 Obese stone formers (i.e., with
a BMI of 25 kg/m2) had higher serum levels of potassium, uric
acid, urea nitrogen, and creatinine compared to the nonobese.
Obese FSFs had decreased urinary pH, whereas obese RSFs did not.
Stone recurrence rates were more frequent in obese stone formers
compared to nonobese ones; however, this was true for FSFs but
not RSFs. Moreover, obese FSFs had a decreased time to stone
recurrence, whereas the time to recurrence was not affected by
obesity for RSFs. In the case of FSFs, obesity was the strongest
predictor of stone recurrence; whereas in RSFs, the strongest
predictor was hypercalcinuria.
3. Imaging tools for investigating urolithiasis
Imaging studies play an important role in diagnosing urolith-
iasis. Many tools are useful, including conventional radiography
(plain KUB), intravenous urography (IVU), ultrasonography (US),
nuclear medicine, computed tomography (CT) (single- or multi-
detector row helical), and magnetic resonance imaging (MRI).
Traditionally, evaluation consisted of conventional radiography
(KUB) followed by IVU. These techniques can be used to detect the
size of the calculi, the point of obstruction, and its severity. Patients
who cannot safely undergo IVU (i.e., patients with acute renal
failure, pregnant patients, and those with an allergy to the iodin-
ated contrast material) can be evaluated for secondary signs of
obstruction (i.e., hydronephrosis) by US or nuclear medicine. In the
past several years, thin-section nonenhanced CT has evolved,
especially with the development of single-detector row helical CT
and, later, multi-detector row CT, as a means to rapidly examine
patients suspected of having urolithiasis but without the limita-
tions of radiography, IVU, US, or nuclear medicine. In many insti-
tutions, nonenhanced CT has largely replaced IVU as the primary
modality for evaluating these patients. Clinical studies investigated
the value of this technology and demonstrated sensitivities for CTof
96e100%, speciﬁcities of 95.5e100%, and accuracies of 96e98%.5e9
This technique has many advantages for patients. It is performed
without intravenous administration of contrast material and can
therefore be performed in patients with a history of severely
impaired renal function or of an allergy to the iodinated contrast
material. The CT study can be performed rapidly, without the need
for the delayed imaging required for IVU. Obstructing ureteral
calculi can be identiﬁed and directly measured, in contrast to the
case with US or nuclear medicine examinations. In addition, it can
reveal extraurinary causes (such as diverticulitis, adnexal masses,
and appendicitis) of ﬂank pain in 16e45% of renal colic
patients.10e12 However, questions remain regarding the optimal use
of this technique because of concerns about radiation exposure and
costs. As noted by Smith et al,43 the skin (entry) dose for a non-
enhanced CT examination (120e140 kVp, 200e300 mAs) is
approximately 3e5 rad (30e50 mGy).10 In contrast, the skin dose
for each IVU radiograph is approximately 0.25e0.30 rad (2.5e3.0
mGy). Recently, Liu et al used nonenhanced helical CT with 7-mm
collimation and a pitch of 2 to reduce the radiation dose.13 Their
measured effective dose equivalent was 2.8 mSv, compared to
a dose of 1.33 mSv for IVU at their institution.
4. Medical treatment
Throughout history, hundreds of natural plant extracts and
more recently, modern synthetic drugs have been proposed to
enhance stone passage. The use of hormones, steroids, nonsteroidal
anti-inﬂammatory drugs, calcium channel blockers, corticosteroids,and adrenergic [alpha] antagonists have all been used to facilitate
stone passage. But most of them lacked scientiﬁc evidence to prove
their efﬁcacy. Multiple clinical trials involving calcium channel
blockers14,15,21e24 and adrenergic [alpha] antagonists (including
tamsulosin, terazosin, and doxazosin)14e20 demonstrated these two
drugs to be clinically efﬁcacious, safe, and well tolerated for medical
explusive therapy. In Taiwan, Wang et al25 conducted a prospective
studywhich clearly showed that 0.4mg tamsulosinor2mg terazosin
daily is safe and effective in increasing the stone expulsion rate and
reducing the expulsion time. Many other clinical studies also used
0.4 mg tamsulosin daily as medical expulsive therapy and showed
that it improves stone passage rates, decreases stone expulsion
times, and reduces the need for analgesic therapy, hospitalization,
and surgery in appropriately selected individuals.Wang et al’s study
further broadened the use of tamsulosin. Their prospective
randomized studies revealed that tamsulosin is also effective in
reducing urinary symptoms and increasing the quality of life related
to double-J stent indwelling.26,27 The use of corticosteroids is efﬁ-
cient only when administered together with alpha1 blockers.18
Oral citrate is one of the most widely used medical therapies for
preventing urinary stone disease. It exerts a preventive effect
through increasing the urinary pH, decreasing Tamm-Horsfall
protein aggregations, and decreasing crystal adhesion to tubular
cells.28 Two hundred and eighty-six natural plant substances
(among which Herniaria hirsuta is one of the most widely used
herbal remedies) have been critically reviewed to elucidate the
mechanism of phytotherapeutic agents used in treating urolith-
iasis.29 These plant-based substances exert their antilithogenic
properties by altering the ionic composition of urine, e.g.,
decreasing the calcium ion concentration or increasing magnesium
and citrate excretion. These remedies can also express diuretic
activity, or they contain saponins that can disaggregate suspensions
of mucoproteins, which are actually promoters of the crystalliza-
tion process. Herniaria hirsuta progressively decreases the adhesion
of calcium oxalate monohydrate crystals to canine kidney cells. It
also exerts a decreasing effect on crystal adhesion in vitro. In
addition, this plant extract can remove crystals already attached to
cell surfaces.30 Cranberry juice is a popular herb, and McHarg et al
found that it increased urinary citrate excretion together with
decreasing the urinary excretion of oxalate and calcium ions
in vivo.31 Kessler et al demonstrated that cranberry juice decreased
the urinary pH with an increase in urinary oxalic acid. They
concluded that cranberry juice acidiﬁes the urine, and it can be
useful for treating brushite and struvite stones, and urinary tract
infections.32 Investigations on grapefruit juice showed that it
increases the urinary excretion of citrate and magnesium together
with mean oxalate and calcium levels.33,34 Seltzer et al studied the
effect of lemonade on treating hypocitruric calcium neph-
rolithiasis.35 They concluded that lemonade juice can be considered
an alternative or adjunct treatment because it leads to a two-fold
increase in urinary citrate. But those studies were performed
with small samples using different treatment doses. These juices
should be re-evaluated in prospective, double-blind, randomized
studies with larger sample sizes to reach a ﬁnal conclusion.
5. Ureteroscopy
EL-Nahas36 reviewed a total of 908 ureteroscopic procedures for
ureteral stones and concluded that semirigid ureteroscopy is a safe
and highly effective treatment modality for ureteral stones. The
complication rate was 6.7%. The stone-free rate after a single ure-
teroscopic intervention was 87%. Favorable results (a stone-free
status was achieved by a single ureteroscopic procedure with no
complications) were documented in 82.7% of cases. Signiﬁcant
factors for unfavorable results (a stone-free status achieved with
Y.-T. Chen / Urological Science 23 (2012) 5e8 7more than one ureteroscopic procedure or ureteroscope procedure
with complications) were proximal ureteral stones, ureteroscopy
done by surgeons other than experienced endourologists, stone
impaction, and stone width (with respective RRs of 4, 2.5, 1.8, and
1.2). Kijvikai37 carried out a systematic review based on the
MEDLINE database between 1997 and 2005 and showed that both
SWL and ureteroscopy provided excellent stone-free rates
(86e90%) for stones of <10 mm, whereas for larger stones, ure-
teroscopy achieved better outcomes than SWL (67% vs. 73%). Ure-
teroscopy was preferred over SWL in patients who were pregnant
or with bleeding diathesis.38 Urolithiasis during pregnancy is
a serious concern because it may be dangerous to the mother and
fetus. Pregnant women with urinary calculi are at signiﬁcantly
greater risk for a preterm delivery compared to women without
stones [adjusted odds ratio (OR), 1.8].39 Lewis et al40 also observed
that patients diagnosed with a stone during pregnancy were at an
increased risk of preterm premature rupture of the membranes
compared to that in patients without stones (7% vs. 2.9%). A
multinational meta-analysis review38 showed that the safety of
ureteroscopic stone removal in pregnant patients did not signiﬁ-
cantly differ from that of nonpregnant patients. There was no
signiﬁcant difference in ureteral injury or urinary tract infection
complication rates between pregnant and nonpregnant patients
(p ¼ 0.191 and 0.597, respectively). Therefore, ureteroscopic stone
removal may reasonably be considered appropriate ﬁrst-line
therapy for pregnant patients with stone disease.
6. SWL
The noninvasiveness of SWL has made it a reasonable ﬁrst-line
treatment for urinary stones since the ﬁrst description by Chaussy
and Schmiedt41 in 1980. The success rate of SWL is inﬂuenced by
several factors, including the stone burden, stone position, stone
composition, patient BMI, and frequency of shock wave delivery. In
1986, Lingeman et al42 reported respective stone-free rates of 95%,
87%, 48%, and 35% for stones of<1,1e2, 2e3, and>3 cm. Compared
to upper- and middle-pole stones, lower-pole stones were consis-
tently associated with decreased stone-free rates following SWL.
A meta-analysis43 of 2927 patients after SWL for lower-pole stones
revealed a stone-free rate of 59.2%. Explanations for this low success
rate include a gravity effect. One study44 of the infundibulopelvic
anatomy disclosed that an infundibulopelvic angle of <70, an
infundibular length of >3 cm, and an infundibular width of <5 mm
were associatedwith a stone clearance rate of<50%. The lower-pole
stone burden is also a pivotal factor in the success of SWL. Sorensen
and Chandhoke45 revealed respective stone-clearance rates of 78%,
73%, 43%, and 30% for patients with lower-pole stones measuring
<5, 5e10, 11e15, and 16e20 mm. Different stone compositions
showed different susceptibilities to SWL. Highly dense stones
(cystine, brushite, and calcium oxalate monohydrate) are more
refractory to SWL owing to their higher densities, whereas less-
dense stones (calcium oxalate dihydrate, hydroxyapatite, and uric
acid) are more susceptible to SWL.46 A preoperative determination
of the stone composition using plain KUB is not reliable. A
prospective study47 using KUB to predict the stone composition
demonstrated only 39% accuracy. Predicting the stone composition
by preoperative CT attenuation values was proposed. Pareek48
demonstrated a signiﬁcant relationship between Houndsﬁeld
units (HUs) and residual stones. The average HU measurement for
the stone-free groupwas 577.8 compared to910.4 for the groupwith
residual stones. Gupta et al49 demonstrated similar results in 112
patients. Patients with a preoperative HU of >750 had a 10.5-fold
greater chance of needing three or more SWL sessions compared
to patients whose HU was <750. The same study also revealed that
the average BMI for the stone-free group was 26.9 kg/m2 comparedwith 30.8 kg/m2 for the residual-stone group. Recent studies sug-
gested that the rate of shockwave delivery can affect the outcome of
SWL. Both in vitro and animal models demonstrated an increased
per shock efﬁciency of stone fragmentation with decreasing shock
frequency.50,51 Pace et al52 in a randomized, double-blind trial,
studied 111 patients treated with 60 shocks/min and 109 patients
treatedwith 120 shocks/min. The success rateswere 75% and 61% in
the 60- and 120-shocks/min groups, respectively. Ameta-analysis53
revealed that patients treated at a rate of 60 shocks/min had
a signiﬁcantly greater likelihood of a successful treatment (risk
difference 10.2, 95% conﬁdence interval 3.7e16.8, p ¼ 0.002).
7. Conclusions
Recent societal changes have caused a decrease in the male-to-
female ratio of the incidence of stones. Obesity is related to an
increased risk of stone formation. KUB is the simplest imaging tool
to diagnose urinary calculi but is not always reliable. Nonenhanced
CT is rapid, speciﬁc, and accurate in assessing urolithiasis with the
limitations of higher costs and irradiation exposure. Medical
expulsive therapy can improve the stone passage rate, decrease
stone expulsive times, and reduce the need for analgesics. SWL is
more effective in treating urinary calculi in a lower-frequency
mode. When performed by experienced hands, ureteroscopy is
safe in managing ureteral stones and is preferred over SWL in
patients with large upper ureter stones, those who are pregnant,
and those with bleeding diathesis.
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